{"brief_title": "Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients", "brief_summary": "The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.", "condition": "Kidney Transplantation", "intervention_type": "Drug", "intervention_name": "Certican", "criteria": "Inclusion Criteria: - Male and female patients no more than 16 years of age. - Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant. - The graft must be functional within 48 hours post transplantation. Exclusion Criteria: - Cold ischemia time greater than 40 hours. - Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs. - Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.", "gender": "All", "minimum_age": "N/A", "maximum_age": "16 Years", "healthy_volunteers": "No", "id": "NCT00098241.xml"}